Amongst the top 10 therapies that contribute to more than 90% of the Indian pharma market, price drove growth in the cardiac segment. The anti-hypertensives, which account for almost 50% of the cardiac segment, is experiencing stagnated volume growth. Lipid-lowering drugs and platelet aggregation inhibitors have shown a relatively higher growth to help boost the cardiac segment. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
